Live Breaking News & Updates on Amgenv Sanofi|Page 5
Stay updated with breaking news from Amgenv sanofi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
2021 US must lead on FRAND; BlackBerry royalties don t impress markets; USPTO Director race narrows; Top IP lessons for biotech SMEs; InterDigital eyes M&A; and much more Everything we covered on IAM over the last seven days – and all you need to know from the global IP market to set yourself up for the start of another busy week The Long Read Data does not have to be an opportunity just for the biggest players, smaller businesses can also get in on the act – but only if they think carefully about IP strategy. BT senior counsel Afzana Anwer explains how SMEs can secure the winning edge. Read more here ....
01 Apr 2021 01 Apr 2021 @IAM Alerts Panasonic is on the offensive in the latest competitor infringement suit to hit the auto supply chain… https://t.co/M16PiE2JeARead more 31 Mar 2021 31 Mar 2021 ....
Surge in Chinese utility models causes concern Grants of the second-tier patent rights increased by 50%, while experts inside and outside of China estimate application growth in 2020 of over 30%. Returning user? Enter your details below to log into your account. E-Mail Address: ....
Sunday, February 14, 2021 While this recent Fed. Cir. decision – Amgen Inc. v. Sanofi, Appeal No. 2020-1074 (Fed. Cir., Feb. 11, 2021) seems predictable, given the fate of antibody claims that recite the target and the function of antibody binding thereto, there are a few interesting wrinkles to comment on. A Fed. Cir. panel of Judges Lourie, Prost and Hughes, Lourie writing, affirmed the district courts finding that Amgen’s claims failed the enablement test of s. 112. Evaluating the Wands factors there are seven of them to determine whether or not the claimed antibodies would require undue experimentation to locate ones falling within the scope of the claims, the panel relied on its fairly extensive precedent, most of it unfavorable to Amgen, and concluded that “lack of enablement [was found] due to the undue experimentation required to make and use the full scope of the claimed compounds that require a particular structure and functionality.” As the panel ....